Trevi Therapeutics, Inc.TRVI stock score: 40/100
$13.72 · +1.55% · Scored Nov 19, 2026
- Technical
- 53
- Fundamental
- 37
- News
- 52
The reading
Trevi Therapeutics (TRVI) scores 40 out of 100, which reads weak, higher than 25% of Healthcare stocks and 23% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 37, technicals 53.
Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Earnings Growth (5-Year) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 47 and contrarian oscillators 53.
News sentiment is neutral at 52; it is shown, not counted in the composite.
Since Aug 22, 2026 the composite has ranged from 38 to 52, and it is down 10 points over the period.
About Trevi Therapeutics
Trevi Therapeutics (TRVI) is a clinical-stage biopharmaceutical company developing Haduvio, an oral extended-release form of nalbuphine, to treat chronic cough. Nalbuphine acts on opioid receptors in the brain and peripheral nervous system, and it is approved in an injectable form for pain. Trevi’s lead program targets chronic cough in people with idiopathic pulmonary fibrosis, a progressive lung disease in which persistent cough is common and has no approved treatment. After positive mid-stage results, it has started late-stage trials in this indication, and it is also studying Haduvio in refractory chronic cough and in cough linked to other interstitial lung diseases. Trevi has no approved products, so it funds its research mainly through equity raises. If approved, Haduvio would earn money from product sales, either through Trevi’s own commercial team or through partners.
Trevi competes with other companies developing chronic cough treatments, including larger drugmakers working on drugs that act through other mechanisms. Its edge rests on a mechanism that acts on the brain’s cough reflex, clinical data showing reduced cough frequency, and a focus on patients with lung disease who have no approved options. Investors who follow TRVI stock tend to watch enrollment and results of its late-stage trials. Feedback from regulators on trial design is closely followed. Safety and tolerability data, cash runway and share dilution are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward TRVI’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
37Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Holding it back
5-year earnings growth evaluates long-term profit trajectory and consistency.
Net income growth against the same quarter a year earlier, weighted toward the latest quarter.
Return on Equity (ROE) measures how efficiently a company generates profits from shareholder equity.
26 weighted scorers; 13 had no data today and are left out rather than counted as zero.
Technical · daily
46Pulling it up
Where the close sits against its 20-day SMA.
Where the close sits against its 50-day SMA.
Performance versus SPY compares the stock's returns to the S&P 500 index.
Holding it back
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
Where the close sits against its 100-day SMA.
Simple Moving Average (100-period) provides a longer-term perspective on price trends.
61 weighted scorers; 4 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 52
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 61 | 1 |
| Daily | 46 | 3 |
| Weekly | 51 | 2 |
| Monthly | 61 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 40 |
| Nov 18, 2026 | 39 |
| Nov 17, 2026 | 39 |
| Nov 16, 2026 | 39 |
| Nov 15, 2026 | 39 |
| Nov 14, 2026 | 39 |
| Nov 13, 2026 | 39 |
| Nov 12, 2026 | 38 |
| Nov 11, 2026 | 48 |
| Nov 10, 2026 | 47 |
| Nov 8, 2026 | 46 |
| Nov 7, 2026 | 46 |
| Nov 6, 2026 | 45 |
| Nov 5, 2026 | 42 |
| Nov 4, 2026 | 46 |
| Nov 3, 2026 | 42 |
| Nov 2, 2026 | 45 |
| Nov 1, 2026 | 45 |
| Oct 30, 2026 | 43 |
| Oct 29, 2026 | 45 |
| Oct 28, 2026 | 43 |
| Oct 27, 2026 | 45 |
| Oct 26, 2026 | 41 |
| Oct 25, 2026 | 41 |
| Oct 24, 2026 | 42 |
| Oct 23, 2026 | 42 |
| Oct 22, 2026 | 43 |
| Oct 21, 2026 | 43 |
| Oct 20, 2026 | 42 |
| Oct 19, 2026 | 40 |
| Oct 18, 2026 | 40 |
| Oct 17, 2026 | 40 |
| Oct 16, 2026 | 40 |
| Oct 15, 2026 | 40 |
| Oct 14, 2026 | 40 |
| Oct 13, 2026 | 41 |
| Oct 12, 2026 | 42 |
| Oct 11, 2026 | 42 |
| Oct 10, 2026 | 42 |
| Oct 9, 2026 | 42 |
| Oct 8, 2026 | 41 |
| Oct 7, 2026 | 41 |
| Oct 6, 2026 | 41 |
| Oct 5, 2026 | 42 |
| Oct 4, 2026 | 43 |
| Oct 3, 2026 | 43 |
| Oct 2, 2026 | 43 |
| Oct 1, 2026 | 44 |
| Sep 30, 2026 | 44 |
| Sep 29, 2026 | 45 |
| Sep 28, 2026 | 44 |
| Sep 27, 2026 | 43 |
| Sep 26, 2026 | 43 |
| Sep 25, 2026 | 44 |
| Sep 24, 2026 | 45 |
| Sep 23, 2026 | 46 |
| Sep 22, 2026 | 46 |
| Sep 21, 2026 | 45 |
| Sep 20, 2026 | 45 |
| Sep 19, 2026 | 45 |
| Sep 18, 2026 | 45 |
| Sep 17, 2026 | 45 |
| Sep 16, 2026 | 44 |
| Sep 15, 2026 | 44 |
| Sep 14, 2026 | 45 |
| Sep 13, 2026 | 45 |
| Sep 12, 2026 | 45 |
| Sep 11, 2026 | 45 |
| Sep 10, 2026 | 45 |
| Sep 9, 2026 | 46 |
| Sep 8, 2026 | 48 |
| Sep 7, 2026 | 48 |
| Sep 6, 2026 | 48 |
| Sep 5, 2026 | 48 |
| Sep 4, 2026 | 48 |
| Sep 3, 2026 | 52 |
| Sep 2, 2026 | 49 |
| Sep 1, 2026 | 47 |
| Aug 31, 2026 | 46 |
| Aug 30, 2026 | 47 |
| Aug 29, 2026 | 47 |
| Aug 28, 2026 | 47 |
| Aug 27, 2026 | 49 |
| Aug 26, 2026 | 49 |
| Aug 25, 2026 | 49 |
| Aug 24, 2026 | 50 |
| Aug 23, 2026 | 50 |
| Aug 22, 2026 | 50 |
Key facts
- Market cap
- $2.0B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 1.12
- Risk grade (1–10)
- 7
- Next earnings
- Nov 9, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| AUPH Aurinia Pharmaceuticals | $2.0B | 73 |
| IMNM Immunome | $2.0B | 36 |
| FTRE Fortrea | $1.9B | 47 |
| HRMY Harmony Biosciences | $1.9B | 72 |
| VERA Vera Therapeutics | $1.9B | 31 |
| ZYME Zymeworks | $1.9B | 53 |
Questions
What is TRVI's stock rating today?
TRVI scores 40/100 (Weak) as of Nov 19, 2026: technical 53, fundamental 37, and news sentiment 52, which is shown but not counted. Scores are recomputed every night.
What does Trevi Therapeutics do?
Trevi Therapeutics (TRVI) is a clinical-stage biopharmaceutical company developing Haduvio, an oral extended-release form of nalbuphine, to treat chronic cough. Nalbuphine acts on opioid receptors in the brain and peripheral nervous system, and it is approved in an injectable form for pain.
Is TRVI stock a buy?
The score is not a buy or sell recommendation. A 40 says the technical and fundamental signals we measure lean weak today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the TRVI score calculated?
87 weighted scorers feed it today: 26 fundamental, scored against Healthcare ranges, and 61 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/trvi/"><img src="https://stocksscores.com/stocks/trvi/badge.svg" alt="TRVI stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/trvi/)